Angion Biomedica is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics to address chronic and progressive fibrotic diseases. Co.'s product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases. ANG-3070 has demonstrated activity as an anti-fibrotic agent in a variety of animal models. Co. is also continuing to develop its preclinical programs. Co.'s ROCK2 program, which is targeted towards the treatment of fibrotic diseases and CYP11B2 program, which is targeted towards diseases related to aldosterone synthase dysregulation. We show 7 historical shares outstanding datapoints in our coverage of ANGN's shares outstanding history.
Understanding the changing numbers of ANGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ANGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ANGN by allowing them to research ANGN shares outstanding history
as well as any other stock in our coverage universe. |
Free ANGN Email Alerts:
Video: Shares Outstanding Importance
